KHK and obesity due to melanocortin 4 receptor deficiency: Based, in part, on the results of this study, our collaborators at Alnylam completed a phase I and are progressing with a phase II clinical trial (NCT05761301) testing KHK siRNA in patients with obesity and diabetes.